The position of these inhibitors in the KRAS G12C lung cancer treatment strategy algorithm is still evolving; primarily, the activity of KRAS G12C may be limited due to the genetic heterogeneity and complex biology of KRAS. This evidence concerns the gene KRAS and lung cancer.